A blast count of at least 20 % was kept to differentiate AML with BCR::ABL1 fusion from chronic myeloid leukaemia (CML), although distinction from CML blast phase is still challenging, thus lack of features of CML prior to or at diagnosis or after therapy is required. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.